STUDY. Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
|
|
- Berniece Simmons
- 5 years ago
- Views:
Transcription
1 ONLINE FIRST STUDY Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis Jashin J. Wu, MD; Kwun-Yee T. Poon, MS; Jennifer C. Channual, MD; Albert Yuh-Jer Shen, MS, MD Objective: To assess whether patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a decreased risk of myocardial infarction (MI) compared with those not treated with TNF inhibitors. Design: Retrospective cohort study. Setting: Kaiser Permanente Southern California health plan. Patients: Patients with at least 3 International Classification of Diseases, Ninth Revision, Clinical Modification, codes for psoriasis (696.1) or psoriatic arthritis (696.0) (without antecedent MI) between January 1, 2004, and November 30, Main Outcome Measure: Incident MI. Results: Of 8845 patients included, 1673 received a TNF inhibitor for at least 2 months (TNF inhibitor cohort), 2097 were TNF inhibitor naive and received other systemic agents or phototherapy (oral/phototherapy cohort), and 5075 were not treated with TNF inhibitors, other systemic therapies, or phototherapy (topical cohort). The median duration of follow-up was 4.3 years (interquartile range, 2.9, 5.5 years), and the median duration of TNF inhibitor therapy was 685 days (interquartile range, 215, 1312 days). After adjusting for MI risk factors, the TNF inhibitor cohort had a significantly lower hazard of MI compared with the topical cohort (adjusted hazard ratio, 0.50; 95% CI, ). The incidence of MI in the TNF inhibitor, oral/phototherapy, and topical cohorts were 3.05, 3.85, and 6.73 per 1000 patientyears, respectively. Conclusions: Use of TNF inhibitors for psoriasis was associated with a significant reduction in MI risk and incident rate compared with treatment with topical agents. Use of TNF inhibitors for psoriasis was associated with a non statistically significant lower MI incident rate compared with treatment with oral agents/phototherapy. Arch Dermatol. 2012;148(11): Published online August 20, doi: /archdermatol Author Affiliations: Departments of Dermatology (Dr Wu) and Cardiology (Dr Shen), Kaiser Permanente Los Angeles Medical Center, Los Angeles, California; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (Ms Poon); and Department of Dermatology, University of California, Irvine (Dr Channual). PSORIASIS IS A CHRONIC SKIN condition that affects approximately 2% to 3% of the population. 1,2 Beyond cutaneous manifestations, psoriasis is a systemic inflammatory state that is associated with an increased risk of cardiovascular diseases, including obesity, 3,4 type 2 diabetes mellitus, 5,6 hypertension, 5,7 dyslipidemia, 3,7 metabolic CME available online at syndrome, 2,8 peripheral vascular disease, 6 atherosclerosis, 9-11 coronary artery calcification, 12 myocardial infarction (MI), 7,13 stroke, 7,14 and cardiac death. 15,16 Psoriasis is also associated with behaviors that worsen cardiovascular risk, such as smoking 4,17 and alcohol intake. 17,18 The effect of systemic treatment for psoriasis on cardiovascular disease has been largely unexplored. It has been suggested that therapeutic use of methotrexate, probably owing to its anti-inflammatory properties, may reduce vascular disease in patients with psoriasis. 19 It is not well described whether treatment with etanercept, 20 infliximab, 21 or adalimumab 22 affects the risk of cardiovascular disease in patients with psoriasis. Abuabara et al 23 recently reported that there does not seem to be a reduced risk of MI in patients with psoriasis receiving systemic therapy (including tumor necrosis factor [TNF] inhibitors) compared with a group undergoing phototherapy. However, there are possible flaws in the study design, such as grouping all systemic therapies, that put the conclusion into question. 24 Author Affil Departments (Dr Wu) and Shen), Kaise Angeles Med Angeles, Cal of Research a Kaiser Perma California, P Poon); and D Dermatology California, Ir Channual). 1244
2 The primary objective of this study was to assess whether patients with psoriasis treated with TNF inhibitors have a decreased risk of MI compared with those not treated with TNF inhibitors (ie, those who received oral agents/phototherapy or topical agents). METHODS DESIGN OVERVIEW This is a retrospective cohort study conducted in the Kaiser Permanente Southern California (KPSC) health plan, a large integrated health maintenance organization that has served approximately 3.2 million members during each of the past 10 years. Membership attrition averages 10% per year. The membership of KPSC composes approximately 15% of the region s population. Its membership demographic, socioeconomic, and racial/ethnic composition are representative of California. 25,26 Health maintenance organization members receive most of their health care at KPSC-owned facilities, including medical centers and offices. However, the health plan is also financially responsible for KPSC members emergency medical care received at facilities outside the health plan. More than 92% of members have prescription drug benefits and obtain their prescription medications from a KPSC pharmacy. All the patients have blood chemistry and other laboratory test benefits. All the data were extracted from HealthConnect, the electronic databases of KPSC clinic and hospital systems. The study protocol was approved by the local institutional review board at KPSC. SETTING AND PARTICIPANTS The study cohort was drawn from KPSC patients with at least 3 recorded diagnosis codes for psoriasis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 696.1) or psoriatic arthritis (ICD-9-CM code 696.0) between January 1, 2004, and November 30, To qualify for study inclusion, a patient must have been a KPSC member for at least 1 year to allow adequate time for comorbidity ascertainment/ documentation and must have had at least 1 medical encounter per year to ensure that the patient was active in health management. The exclusion criterion was a history of MI (ICD-9-CM code 410.XX or 412) documented prior to the third psoriasis diagnosis code. Each patient was assigned to 1 of 3 mutually exclusive cohorts. Patients with psoriasis who received etanercept, infliximab, or adalimumab for at least 2 consecutive months during the study were analyzed as the TNF inhibitor cohort, regardless of changes in treatment regimen, discontinuation or restarting TNF inhibitor use, or use combined with an oral agent or phototherapy. The TNF inhibitor naive patients who received oral agents (ie, cyclosporine, acitretin, and methotrexate) or phototherapy (broad-band UV-B, narrow-band UV-B, or psoralen UV-A) formed the oral/phototherapy cohort. These patients were grouped together since the amount of psoriasis was severe enough to justify more aggressive therapy than topical agents and dermatologists generally consider oral therapy or phototherapy as the next step up before prescribing a TNF inhibitor. Patients who were not treated with TNF inhibitors, oral agents, or phototherapy but were treated with topical agents formed the topical cohort. We define severe disease as the use of any systemic therapy or phototherapy and mild disease as the use of topical agents and the nonuse of systemic therapy or phototherapy. 7,13-16 COVARIATE ASCERTAINMENT Age was calculated from date of birth until the third psoriasis ICD-9-CM code and was measured as a continuous variable. Common MI risk factors were identified using ICD-9-CM codes and KPSC electronic medical records and included adultonset diabetes mellitus (code 250.X), hypertension (codes 401.0, , , 401.1, , , 401.9, , and ), dyslipidemia (codes and 272.9), active/ current smoking, and obesity (defined as a body mass index 30 [calculated as weight in kilograms divided by height in meters squared]). These risk factors were identified at any time during the study. Prescription drugs that may affect incident MI risk were identified using the KPSC pharmacy database and included statins and -blockers. Treatment with methotrexate has previously been suggested to possibly lower MI risk in patients with psoriasis. 19 However, in the univariable analysis of this cohort, methotrexate use (n=1983) was not associated with MI risk (hazard ratio [HR], 0.89; 95% CI, ) and was not further analyzed. Also in the univariable analysis of this cohort, obesity (n=8464; HR, 0.86; 95% CI, ) and smoking (1104; 0.87; ) were not associated with MI risk and were not further analyzed. The diagnostic accuracy of ICD-9-CM codes for diabetes mellitus and hypertension in the KPSC administrative database has been previously validated by manual medical record review to have a of 0.82 to The numbers of psoriasis diagnoses or medical encounters, considered in this study as a proxy for health care resource use, were also entered into the models as covariates. OUTCOMES AND FOLLOW-UP For patients in the TNF inhibitor cohort, treatment onset was defined by the date of the patient s first TNF inhibitor dispensation after the third psoriasis ICD-9-CM code. For the oral/ phototherapy cohort, follow-up began on the date of the first dispensation of any non TNF inhibitor systemic agent or the first day of phototherapy after the third psoriasis ICD-9-CM code. For patients in the topical cohort, follow-up began on the date of the third psoriasis ICD-9-CM code. Follow-up ended (was censored) with the first occurrence of any of the following: (1) fatal or nonfatal MI, (2) death during the study, (3) disenrollment from KPSC, or (4) October 28, 2011 (the end of the study). Cause of death was obtained from California state death certificates. The mortality file consolidates information from KPSC hospital deaths and California state death records. Death records are linked to patients based on linkage weight calculated using a probabilistic method based on demographic information. For patients who did not experience any of these events, the last visit before the end of the study was used as that patient s end date to minimize information bias. STATISTICAL ANALYSIS Demographic and clinical characteristics of patients were summarized by frequency (percentage) for categorical variables and mean (SD) for continuous variables; 2 and unpaired t tests, respectively, were used to compare their association with the outcome variable. The primary analyses were conducted using Cox proportional hazards regression. Univariate Cox proportional hazards regression was used to screen for potential significant association between each covariate and the outcome. Covariates with P.15 were selected for multivariable model building using the backward selection method until the most parsimonious model was reached. To further examine the association between the outcome and the covariates, we performed subset analyses using 1245
3 Membership database Diagnosis database Patients with any PsO or PsA Dx during Patients with 3 Dx during Patients Patients Patients with eligible enrollment criteria (minimum 1 y) with eligible visit criteria (minimum 1 per y) with no previous MI 9106 Patients meet the 3 eligibility criteria 8845 Adult patients meet the 3 eligibility criteria Figure. CONSORT diagram for the cohort of patients with psoriasis (PsO). Dx indicates diagnosis; MI, myocardial infarction; PsA, psoriatic arthritis. Cox proportional hazards regression, adjusting for each of the individual cardiac risk factors and medications that are known to reduce MI risk in addition to age, sex, and person-years among the cohorts. Poisson regression was used to examine the incidence rate of MI in each treatment group. The incidence rates of MI in the 3 cohorts (TNF inhibitors, oral/phototherapy, and topical) were first compared using unadjusted Poisson regression modeling. The rates were then adjusted for age, sex, and personyears of observation and were compared with yield incidence rate ratios. All the statistical analyses were performed using a commercially available software program (SAS Enterprise Guide, version 4.3; SAS Institute, Inc). RESULTS Between January 1, 2004, and November 30, 2010, there was a cohort of 8845 patients with psoriasis (Figure). Of KPSC members in 2008, (0.58%) had a diagnosis of psoriasis, 1759 (0.06%) had a diagnosis of psoriatic arthritis, 1170 (0.04%) had both, and (0.60%) had a diagnosis of any psoriatic disease. The cohort mean age was 52.8 years, and 50.0% were men (Table 1). In this cohort, 5075 (57.4%) were not treated with any systemic therapy or phototherapy and were assigned to the topical cohort. Of the remaining patients, 1673 (18.9%) were treated with TNF inhibitors for at least 2 consecutive months, and 2097 (23.7%) were treated with oral systemic agents or phototherapy. The cohort was observed for a median of 4.3 years (interquartile range, 2.9, 5.5 years), resulting in patient-years of follow-up. The data for 8624 patients (97.5%) were censored: 402 (4.5%) for death and 1818 (20.6%) for membership discontinuation, and 6404 (72.4%) were observed to the end of the study. The overall cohort experienced 221 episodes (2.5%) of incident MI, for an overall rate of 5.21 per 1000 patient-years. The incident rates of MI for the TNF inhibitor, oral/ phototherapy, and topical cohorts were 3.05, 3.85, and 6.73 per 1000 patient-years, respectively (P.001) (Table 2). In pairwise comparisons of the 3 cohorts, the TNF inhibitor cohort had a statistically significant 55% reduction in MI incidence compared with the topical cohort (Table 3). The oral/phototherapy cohort had a statistically significant 43% reduction in MI incidence compared with the topical cohort. The TNF inhibitor cohort Table 1. Cohort Characteristics a Characteristic Topical (n = 5075) Treatment Cohort b Oral/Phototherapy (n = 2097) TNF Inhibitor (n = 1673) Total (N = 8845) TNF Inhibitor vs Topical P Value Oral/Phototherapy vs Topical Male sex, No. (%) 2427 (47.8) 1086 (51.8) 913 (54.5) 4426 (50) Age, mean (SD), y 54.6 (15.2) 53.0 (13.6) 47.0 (13.0) 52.8 (14.7) Psoriatic arthritis, No. (%) 339 (6.7) 522 (24.9) 827 (49.4) 1688 (19.1) Risk factors for MI, No. (%) Diabetes mellitus 1385 (27.3) 561 (26.8) 432 (25.8) 2378 (26.9) Dyslipidemia 3235 (63.7) 1283 (61.2) 898 (53.7) 5416 (61.2) Hypertension 3100 (61.1) 1284 (61.2) 926 (55.3) 5310 (60.0) Smoking c 596 (12.1) 261 (12.9) 247 (15.0) 1104 (12.8) Obesity c 2057 (42.4) 879 (44) 804 (49.8) 3740 (44.2) Concurrent medications, No. (%) -Blockers 1498 (29.5) 615 (29.3) 416 (24.9) 2529 (28.6) Statins 2426 (47.8) 969 (46.2) 719 (43.0) 4114 (46.5) Methotrexate (42.0) 940 (56.2) 1820 (20.6) Abbreviations: MI, myocardial infarction; TNF, tumor necrosis factor. a As post hoc analyses, pairwise comparisons were made between the TNF inhibitor and topical cohorts and between the oral/phototherapy and topical cohorts. The 2-sample t test was used for continuous variables, and the 2 test was used for categorical variables. The Bonferroni correction was used to screen for significant association; thus, the cutoff value was.053. b See the Setting and Participants subsection of the Methods section for a description of the cohorts. c Data are missing for some patients in each cohort. 1246
4 Table 2. Incidence Rates of MI by Treatment Received Treatment Cohort a Characteristic Topical Oral/Phototherapy TNF Inhibitor P Value MI events, No Patient follow-up, y Incidence rate, per 1000 patient-years Abbreviation: MI, myocardial infarction. a See the Setting and Participants subsection of the Methods section for a description of the cohorts. Table 3. Pairwise Comparison of MI Rate Ratios Pair MI Rate Ratio (95% CI) P Value TNF inhibitors vs topical agents 0.45 ( ).001 Oral agents/phototherapy 0.57 ( ).001 vs topical agents TNF inhibitors vs oral agents/phototherapy 0.79 ( ).34 Abbreviations: MI, myocardial infarction; TNF, tumor necrosis factor. had a nonsignificant 21% reduction in MI incidence compared with the oral/phototherapy cohort. The median duration of TNF inhibitor therapy was 685 days (interquartile range, 215, 1312 days). Adjusting for common characteristics and medications that may affect MI risk, use of TNF inhibitors was associated with a 50% lower hazard of incident MI (HR, 0.50; 95% CI, ) compared with the topical cohort (Table 4). Patients in the oral/phototherapy cohort had a 46% lower risk of MI compared with the topical cohort (HR, 0.54; 95% CI, ). Increasing age, male sex, and the classic MI risk factors were strongly associated with a greater risk of MI in this cohort of patients with psoriasis, whereas statin use was protective. -Blockers did not confer statistically significant results. Psoriatic arthritis was associated with a 63% increased risk of MI compared with psoriatic patients without arthritis. In sensitivity analyses restricted to having at least 3 ICD-9-CM codes with a time-dependency analysis comparing TNF inhibitor use, methotrexate use, and topical agent use, the results were similar (Table 5). In a multivariable model with an age stratification of patients 60 years and younger, the TNF inhibitor cohort had a statistically significant 54% lower hazard of incident MI (HR, 0.46; 95% CI, ) compared with the topical cohort, and the oral/phototherapy cohort had a nonsignificant 40% lower risk of MI compared with the topical cohort (0.60; ) (Table 6). In the group older than 60 years, the TNF inhibitor cohort had a significant 68% lower hazard of incident MI (HR, 0.32; 95% CI, ) compared with the topical cohort, and the oral/phototherapy cohort had a significant 65% lower risk of MI compared with the topical cohort (0.35; ) (Table 6). When using the median duration of TNF inhibitor therapy of 685 days as the cutoff point and 685 days and less as the reference group (n = 840), there was a nonsignificant trend that longer duration of TNF inhibitor Table 4. Multivariable Proportional Hazards Model Assessing Factors Associated With Incident Myocardial Infarction Factor Hazard Ratio (95% CI) P Value TNF inhibitors 0.50 ( ).003 Oral agents/phototherapy 0.54 ( ).001 Topical agents 1 [Reference] Female sex 0.51 ( ).001 Age 65 y 0.47 ( ).001 Psoriatic arthritis 1.63 ( ).006 Diabetes mellitus 2.23 ( ).001 Dyslipidemia 6.05 ( ).001 Hypertension 6.58 ( ).001 -Blockers 1.09 ( ).56 Statins 0.31 ( ).001 Abbreviation: TNF, tumor necrosis factor. therapy (n = 833) was associated with a higher MI risk (HR, 1.36; 95% CI, ; P =.43) compared with shorter duration. COMMENT In the multivariable model that included the 3 cohorts, the use of TNF inhibitors and oral agents/phototherapy for psoriasis was associated with statistically significant reductions (50% and 46%, respectively) in MI risk compared with patients treated with topical agents. It seems that controlling psoriasis with aggressive therapy and, thus, lowering inflammation leads to a reduction in MI risk. When making head-to-head comparisons, there is a trend that the use of TNF inhibitors is associated with a non statistically significant lower MI incident rate compared with psoriatic patients treated with oral agents/ phototherapy. The results of this study confirmed that psoriasis is associated with an increased risk of diabetes, 5,6 hypertension, 5,7 and dyslipidemia. 3,7 As can be expected, a large proportion (49.4%) of patients in the TNF inhibitor cohort had psoriatic arthritis. In the age-stratified multivariable model, it seems that treatment with TNF inhibitors and oral agents/ phototherapy may have stronger protective effects in the group older than 60 years compared with the group 60 years and younger. One reason for this is that older patients are more likely to have type 2 diabetes mellitus, and the benefits of TNF inhibitor use may be mediated through improving risk of type 2 diabetes mellitus. Solomon et al 28 recently reported that in those with psoriasis 1247
5 Table 5. Multivariable Proportional Hazards Model Assessing Factors Associated With Incident Myocardial Infarction Comparing TNF Inhibitors vs Methotrexate vs Topical Agents Factor Hazard Ratio (95% CI) P Value TNF inhibitors 0.50 ( ).004 Methotrexate 0.52 ( ).01 Topical agents 1 [Reference] Female sex 0.51 ( ).001 Age 65 y 0.45 ( ).001 Psoriatic arthritis 1.63 ( ).01 Diabetes mellitus 2.22 ( ).001 Dyslipidemia 5.30 ( ).001 Hypertension 8.38 ( ).001 -Blockers 1.06 ( ).68 Statins 0.31 ( ).001 Abbreviation: TNF, tumor necrosis factor. Table 6. Multivariable Proportional Hazards Model Assessing Factors Associated With Incident Myocardial Infarction in Patients 60 Years and Younger vs Older Than 60 Years Factor Hazard Ratio (95% CI) P Value Patients 60 y (n = 6138) TNF inhibitors (n = 1427) 0.46 ( ).02 Oral agents/phototherapy 0.60 ( ).06 (n = 1468) Topical agents (n = 3243) 1 [Reference] Female sex 0.51 ( ).003 Psoriatic arthritis 1.48 ( ).16 Diabetes mellitus 2.41 ( ).001 Dyslipidemia 7.42 ( ).001 Hypertension 3.18 ( ).001 -Blockers 1.55 ( ).052 Statins 0.52 ( ).01 Patients 60 y (n = 2707) TNF inhibitors (n = 246) 0.32 ( ).006 Oral agents/phototherapy 0.35 ( ).001 (n = 629) Topical agents (n = 1832) 1 [Reference] Female sex 0.54 ( ).001 Psoriatic arthritis 1.57 ( ).055 Diabetes mellitus 2.20 ( ).001 Dyslipidemia 5.90 ( ).001 Hypertension ( ).001 -Blockers 0.84 ( ).31 Statins 0.20 ( ).001 Abbreviation: TNF, tumor necrosis factor. or rheumatoid arthritis treated with a TNF inhibitor or hydroxychloroquine (but not methotrexate), the adjusted risk of incident diabetes mellitus was lower than that in those treated with nonbiological diseasemodifying antirheumatic drugs. As some studies 29,30 have shown that TNF inhibition therapy improves insulin metabolism, this class of therapy may affect atherosclerotic risk via this mechanism as well. An elevated level of C-reactive protein (CRP), a marker for inflammation, is associated with an increased risk of MI. Lowering CRP levels with statin therapy is associated with significantly lower incidences of MI, stroke, and other major cardiovascular events. 31 Strober et al 32 examined the effect of etanercept therapy on highsensitivity CRP in patients with psoriasis. Psoriatic patients with and without psoriatic arthritis were noted to have elevated baseline high-sensitivity CRP levels. After 12 weeks of etanercept therapy, high-sensitivity CRP levels were significantly reduced regardless of concomitant statin therapy. Using data from the large CORRONA (Consortium of Rheumatology Researchers of North America) registry of patients with rheumatoid arthritis, another inflammatory disease associated with cardiovascular disease, the investigators found that treatment with TNF antagonists was associated with a reduced risk of cardiovascular events (HR, 0.39; 95% CI, ), including nonfatal MI (0.24; ), compared with nonbiological disease-modifying antirheumatic drugs. 33 Methotrexate therapy had no effect on cardiovascular events (HR, 0.94; 95% CI, ). 33 The present study is consistent with these previous studies and adds support to the hypothesis that TNF inhibition may lower the risk of MI in patients with systemic inflammatory conditions, such as psoriasis. This study has several strengths: KPSC has many patients with psoriasis, a stable membership, and accurate diagnosis coding of psoriasis, MI, and other medical comorbidities. This allowed a substantial collection of cumulative longitudinal follow-up (patient-years of followup), giving the study adequate power to capture relatively uncommon events, such as MI. Furthermore, prescription drug use in the study cohort was well documented since more than 90% of all the prescriptions of KPSC members are filled in a health plan pharmacy (internal records). The study results are generalizable to other psoriatic patients who are from an insured and ethnically diverse population. Based on internal documentation for the KPSC database, the accuracy and completeness for all the variables (except smoking) were in the upper 90% range. We believe that there is minimal selection bias as to why some patients with severe psoriasis were treated with TNF inhibitors vs oral therapy or phototherapy. The presence of psoriatic arthritis could influence a dermatologist to more likely prescribe a TNF inhibitor. An older age may reduce the likelihood of that patient receiving a TNF inhibitor since Medicare patients have less coverage of prescription benefits for the costly TNF inhibitors and older patients are more likely to have a recent history of cancer, which is a contraindication for TNF inhibitor therapy. However, psoriatic arthritis and age are already adjusted for in the multivariable analysis. A history of MI, diabetes, hypertension, or dyslipidemia would not affect the prescribing habits for a TNF inhibitor. However, there are some limitations to this study. Owing to the nature of the data obtained from community practice, severity of psoriasis as measured by the Psoriasis Area and Severity Index or body surface area is unavailable. Thus, it is possible that patients with severe psoriasis based on the Psoriasis Area and Severity Index or body surface area chose not to receive any systemic therapy and, thus, were placed in the topical cohort. We included all types of diabetes and did not limit to type
6 diabetes mellitus. Data for smoking was 5% incomplete, which could explain why smoking was not found to be associated with increased MI risk. Waist measurement and not body mass index may be the best indicator of obesity-related diseases. 34 Obtaining mortality data generally has a 1-year lag period, so the period between January 1, 2011, and October 28, 2011, captured only MI incidence and not any deaths caused by MIs. In the primary multivariable analysis, we assumed that medication effect remained until the end of follow-up. This is equivalent to an intent-to-treat analysis, which improves the rigor of the analysis. Furthermore, a timedependency analysis was not used in the primary multivariable analysis since it would be difficult to separate effects of changing therapies and combinations of therapies, and it would not account for any postponed remodeling of arthrosclerosis or other beneficial internal effects that the use of TNF inhibitors or oral agents/ phototherapy may induce. However, a sensitivity analysis using a time-dependency analysis comparing TNF inhibitors, methotrexate, and topical agents resulted in a similar lower HR for MI risk in the TNF inhibitor cohort. Not all the drugs that may affect an individual s MI risk were entered into the models. In particular, overthe-counter nonsteroidal anti-inflammatory drugs, such as aspirin, may have been used differently in these psoriasis cohorts and could not be adjusted for. We also did not account for the duration and dosing of statins, -blockers, or methotrexate. It is possible that this confounded the association of -blockers or methotrexate with the risk of MI. We also did not account for the duration and dosing of the other therapies in the oral/ phototherapy cohort. Almost 20.6% of the cohort disenrolled from the insurance plan, so there is a potential for not capturing outcomes. These were generally younger patients in the age range of 40 years. This group is more dynamic in terms of moving and also more at risk for unemployment and other significant life changes and, thus, their high disenrollment is to be expected in any database. One study 35 reported that patients having at least 3 ICD-9-CM codes for psoriasis in retrospective studies would have a high positive predictive value for psoriasis and that there is a potential for misclassification error that might occur with using only 1 psoriasis diagnostic code for the primary analysis. In the present study, the sensitivity analyses restricted to 1 ICD-9-CM code (n = ) showed that the HR and incidence rates (analysis not shown) remained consistent with those of the primary analysis performed with 3 ICD-9-CM codes. In conclusion, to our knowledge, this is the first largescale retrospective cohort study to show that the use of TNF inhibitors for psoriasis is associated with a clinically and statistically significant reduction in MI risk and incident rate compared with the use of topical agents for psoriasis. There is a trend that the use of TNF inhibitors for psoriasis is associated with a non statistically significant lower MI incident rate compared with the use of oral agents/phototherapy. The use of oral agents/ phototherapy for psoriasis is also associated with a statistically significant reduction in MI risk and incident rate compared with the use of topical agents for psoriasis. Future research endeavors will report whether there are differences based on type of TNF inhibitor. Future prospective studies are needed and warranted to determine whether the use of TNF inhibitors may reduce the risk of major adverse cardiovascular events in patients with systemic inflammatory conditions. Accepted for Publication: June 12, Published Online: August 20, doi: /archdermatol Correspondence: Jashin J. Wu, MD, Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, 1515 N Vermont Ave, Fifth Floor, Los Angeles, CA (jashinwu@hotmail.com). Author Contributions: Drs Wu and Shen and Ms Poon had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Wu and Channual. Acquisition of data: Poon. Analysis and interpretation of data: Wu, Poon, Channual, and Shen. Drafting of the manuscript: Wu and Poon. Critical revision of the manuscript for important intellectual content: Wu, Channual, and Shen. Statistical analysis: Poon. Obtained funding: Wu. Administrative, technical, and material support: Wu, Channual, and Shen. Study supervision: Wu and Shen. Financial Disclosure: Dr Wu has received research grants from Abbott Laboratories, Amgen, and Pfizer that were not directly related to this study. Funding/Support: This project was supported in whole by Kaiser Permanente s Garfield Memorial Fund. Role of the Sponsor: The Garfield Memorial Fund had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. REFERENCES 1. Hinchman KF, Liao W, Koo J, Wu JJ. Current and potential applications of pharmacogenetics in the treatment of psoriasis. In: Koo JY, Lebwohl MG, Lee CS, Weinstein GD, Gottlieb A, eds. Moderate-to-Severe Psoriasis. 3rd ed. New York, NY: Informa Healthcare USA Inc; 2009: Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor- blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther. 2009;22(1): Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4): Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12): Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009; 145(4): Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6): Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159 (4): Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, Arch Dermatol. 2011;147(4): El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2010;24(6):
7 10. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56(4): Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, Dermatology. 2008;217(1): Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2): Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10): Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8): Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Causespecific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3): Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999; 135(12): Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol. 2010; 146(12): Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2): Leonardi CL, Powers JL, Matheson RT, et al; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349(21): Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271): Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58(1): Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165 (5): Wu JJ, Channual JC, Dann F. Association of systemic psoriasis therapies and incidence of myocardial infarction. Br J Dermatol. 2012;166(1): Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39(10): Wu JJ, Black MH, Smith N, Porter AH, Jacobsen SJ, Koebnick C. Low prevalence of psoriasis among children and adolescents in a large multiethnic cohort in southern California. J Am Acad Dermatol. 2011;65(5): Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. JAm Coll Cardiol. 2007;50(4): Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA.2011;305(24): Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4): Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(9): Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2): Greenberg JD, Kremer JM, Curtis JR, et al; CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4): Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79(3): Icen M, Crowson CS, McEvoy MT, Gabriel SE, Maradit Kremers H. Potential misclassification of patients with psoriasis in electronic databases. J Am Acad Dermatol. 2008;59(6):
To order reprints or e-prints of JDD articles please contact SPECIAL TOPIC. American Medical Group Association, Alexandria, VA c
February 2015 159 Volume 14 Issue 2 Copyright 2015 ORIGINAL ARTICLES SPECIAL TOPIC No Association Between TNF Inhibitor and Methotrexate Therapy Versus Methotrexate in Changes in Hemoglobin A1C and Fasting
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationDermatologists Practices and Attitudes towards the Management of Moderate to Severe Psoriasis in Riyadh City, Saudi Arabia
Dermatologists Practices and Attitudes towards the Management of Moderate to Severe Psoriasis in Riyadh City, Saudi Arabia Mona A. Atwa 1 and Lamiaa A Fiala 2 1 Dermatology and Venereology Department,
More informationRotating night shift work and risk of psoriasis in US women
Rotating night shift work and risk of psoriasis in US women The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published
More informationUse of medical record databases to study psoriasis
Use of medical record databases to study psoriasis Joel M. Gelfand, MD, MSCE Professor of Dermatology and Epidemiology Vice Chair for Clinical Research Medical Director, Clinical Studies Unit Director,
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationActual use of medications is important for payers
ORIGINAL RESEARCH and Dosing for Plaque Psoriasis and Psoriatic Arthritis Machaon Bonafede, PhD, MPH; Derek H. Tang, PhD, BSPharm; Kathleen Wilson, MPH; Alice Huang, MS; David J. Harrison, PhD; and Bradley
More informationPsoriasis in Jordan: a single center experience
Psoriasis in Jordan: a single center experience Shefaa Almashagbeh MD *, Deifallah Alsharari MD *, Hayat Khasawneh MD *, Diana Aljammal * MD, Hamzeh Al-housamieh MD* ABSTRACT Objectives: To evaluate the
More informationOVERVIEW OF ADVERSE CARDIOVASCULAR EVENTS IN THE BRODALUMAB PSORIASIS STUDIES
OVERVIEW OF ADVERSE CARDIOVASCULAR EVENTS IN THE BRODALUMAB PSORIASIS STUDIES Bruce Strober, 1,2 Lawrence F. Eichenfield, 3 April Armstrong, 4 Alice Gottlieb, 5 Kenneth Gordon, 6 Tina Lin, 7 Radhakrishnan
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationIncidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
ORIGINAL ARTICLE See related commentary on pg 2308 Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis Eleanor J. Samarasekera 1, Julie M. Neilson 1,
More informationThe Risk of Stroke in Patients with Psoriasis
ORIGINAL ARTICLE The Risk of Stroke in Patients with Psoriasis Joel M. Gelfand 1,2, Erica D. Dommasch 1, Daniel B. Shin 1, Rahat S. Azfar 1,2, Shanu K. Kurd 1, Xingmei Wang 2 and Andrea B. Troxel 2,3 Psoriasis
More informationEtanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
Adv Ther (2012) 29(8):691 697. DOI 10.1007/s12325-012-0039-3 ORIGINAL RESEARCH Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan Benjamin
More informationJacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,
More informationInsights from the Clalit Health Services database about Psoriasis Research using BIG DATA Arnon D. Cohen, MD, MPH, PHD
Insights from the Clalit Health Services database about Psoriasis Research using BIG DATA Arnon D. Cohen, MD, MPH, PHD Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences,
More informationSTUDY. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
STUDY Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis Lidian L. A. Lecluse, MD; Rieke J. B. Driessen, MD; Phyllis I. Spuls, MD, PhD; Elke M.
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationCoronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography
Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography April W. Armstrong, MD, MPH a, *, Caitlin T. Harskamp, BA a, Lynda Ledo, BS a, Jason H. Rogers, MD b, and Ehrin J. Armstrong,
More informationDevelopments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030
Developments in Psoriasis Management 2014 Celgene Corporation 07/14 USII-CELG140030 Psoriasis (PsO) Is a Chronic Inflammatory Disease That Can Impact Patients Health-Related Quality of Life PsO is a chronic
More informationClinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18
Clinical Policy: (Siliq) Reference Number: CP.PHAR.375 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationINDIVIDUALS WITH SYSTEMIC INFLAMmatory
ORIGINAL CONTRIBUTION Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis Daniel H. Solomon, MD, MPH Elena Massarotti, MD Rajesh
More informationNo Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 4 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION No
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? What does this study add? EPIDEMIOLOGY
EPIDEMIOLOGY BJD British Journal of Dermatology Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States*
More informationDeclaration of Conflict of Interest. No potential conflict of interest to disclose with regard to the topics of this presentations.
Declaration of Conflict of Interest No potential conflict of interest to disclose with regard to the topics of this presentations. Clinical implications of smoking relapse after acute ischemic stroke Furio
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationApproximately 3% of the US adult population,
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More informationUstekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese
Hong Kong J. Dermatol. Venereol. (2011) 19, 59-64 Original Article Ustekinumab for severe treatment-resistant psoriasis: a 24-week pilot study in Hong Kong Chinese Ustekinumab SKF Loo, KH Lau, KM Ho Introduction:
More informationRheumatoid Arthritis: An update for non rheumatologists
Rheumatoid Arthritis: An update for non rheumatologists Dimitrios Pappas, M.D., M.P.H. Assistant Professor of Medicine Columbia University, College of Physicians & Surgeons Director of Rheumatology Athens
More informationA nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD
The Association of Clinical Symptomatic Hypoglycemia with Cardiovascular Events and Total Death in Type 2 Diabetes Mellitus A nationwide population-based study Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD Taipei
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationTHE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationTHE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE THERAPY OF THE REBEL SEVERE PSORIAZIS WITH BIOLOGICAL PREPARATS Mădălina FRÎNCU 1 Abstract: Biological
More information- Clinical Background, Motivation and my Experience at F2F meeting
Predicting randomized clinical trial results with realworld evidence: A case study in the comparative safety of tofacitinib, adalimumab and etanercept in patients with rheumatoid arthritis - Clinical Background,
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationJ. Gelfand 1, A. Joshi 2, D. Shin 1, A. Dey 2, D. Torigian 1, D. Rader 1, M. Playford 2, M. Ahlman 2, A. Alavi 1, N. Mehta 2.
A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial Abstract 393 J. Gelfand 1,
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationFinland and Sweden and UK GP-HOSP datasets
Web appendix: Supplementary material Table 1 Specific diagnosis codes used to identify bladder cancer cases in each dataset Finland and Sweden and UK GP-HOSP datasets Netherlands hospital and cancer registry
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationSTUDY. Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis. Data From National Psoriasis Foundation Survey Panels
STUDY Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis Data From National Psoriasis Foundation Survey Panels Tina Bhutani, MD; Jillian W. Wong, MS; Bruce F. Bebo Jr, PhD; April
More informationThe Effect of Statin Therapy on Risk of Intracranial Hemorrhage
The Effect of Statin Therapy on Risk of Intracranial Hemorrhage JENNIFER HANIFY, PHARM.D. PGY2 CRITICAL CARE RESIDENT UF HEALTH JACKSONVILLE JANUARY 23 RD 2016 Objectives Review benefits of statin therapy
More informationLucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:
Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTable S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cosentyx, Cosentyx Sensoready) Reference Number: HIM.PA.SP29 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See
More informationRESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access
open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
More informationObesity and the risk of psoriatic arthritis: a population-based study
1 Department of Science, Education, and Innovation, Landspitali University Hospital, Fossvogur, Reykjavik, Iceland 2 The Clinical Epidemiology Unit, Department of Medicine Boston University School of Medicine,
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationSUPPLEMENTARY DATA. Table of Contents
Table of Contents Supplemental Figure S1. Kaiser Permanente Diabetes Registry Patient Flow Diagram Supplemental Table S1. Diagnostic and procedure codes and frequency of events during follow-up for outcomes
More informationRisk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study
Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j895 (Published
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationBiologic Therapies for Psoriasis. A Systematic Review
Biologic Therapies for Psoriasis. A Systematic Review WOLF-HENNING BOEHNCKE, JÖRG PRINZ, and ALICE B. GOTTLIEB ABSTRACT. Alefacept, efalizumab, etanercept, and infliximab are currently approved for the
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
More informationThe Dermatology Clinical Effectiveness Research Network (DCERN): Early Findings for Psoriasis
The Dermatology Clinical Effectiveness Research Network (DCERN): Early Findings for Psoriasis Joel M. Gelfand, MD, MSCE Medical Director, Clinical Studies Unit Assistant Professor of Dermatology and Epidemiology
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationBJD. Summary. British Journal of Dermatology THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationSupplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease
ORIGINAL INVESTIGATION Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease Vicki A. Jackson, MD; Howard D. Sesso, ScD; Julie E. Buring, ScD; J. Michael Gaziano, MD Background:
More informationAnalysis of Cardiovascular Risk Factors and Metabolic Syndrome in Korean Patients with Psoriasis
Ann Dermatol Vol. 24, No. 1, 2012 http://dx.doi.org/10.5021/ad.2012.24.1.11 ORIGINAL ARTICLE Analysis of Cardiovascular Risk Factors and Metabolic Syndrome in Korean Patients with Psoriasis Gun-Wook Kim,
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationLack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H.
More informationRacial and ethnic disparities in diabetes risk after gestational diabetes mellitus
Diabetologia (2011) 54:3016 3021 DOI 10.1007/s00125-011-2330-2 ARTICLE Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus A. H. Xiang & B. H. Li & M. H. Black & D. A. Sacks
More informationDemographic Trends and Complication Rates in Arthroscopic Elbow Surgery
Demographic Trends and Complication Rates in Arthroscopic Elbow Surgery Natalie L. Leong 1 *, Jeremiah R. Cohen 1, Elizabeth Lord 1, Jeffrey C. Wang 2, David R. McAllister 1, and Frank A. Petrigliano 1
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationApproximately 73.6 million adults in the United States have
n clinical n Hypertension Treatment and Control Within an Independent Nurse Practitioner Setting Wendy L. Wright, MS; Joan E. Romboli, MSN; Margaret A. DiTulio, MS, MBA; Jenifer Wogen, MS; and Daniel A.
More informationClinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationAssociation of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction
CLINICAL SCIENCE Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction Virginia A. Triant, MD, MPH,* James B. Meigs, MD, MPH, and Steven K. Grinspoon, MD Objective: To investigate
More informationDisclosures. Evidence Based Medicine. Infections in SLE and LN Patients. Aim
Serious Infection Rates among Patients with Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants None Disclosures Candace H. Feldman, MD, MPH 1,2 Linda T. Hiraki, MD, SM, ScD 3
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More information